Hanmi’s Amodipin touted as innovation product

Published: 2008-07-11 06:55:00

Updated: 2008-07-11 06:55:00

Hanmi Pharm’s Amodipin (amlodipine camsylate), was recognized as one of 14 innovation products in Korea, according to a report released by the Samsung Economic Research Institute.

The institute said the successful development of Amodipin was chiefly attributed to Hanmi CEO’s direct involvemen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK